RNA News and Research

RSS

Ribonucleic acid (RNA) is a biologically important type of molecule that consists of a long chain of nucleotide units. Each nucleotide consists of a nitrogenous base, a ribose sugar, and a phosphate.

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

SeraCare Life Sciences launches new products to aid discovery and development of drugs and diagnostics

SeraCare Life Sciences, Inc. announced today that the Company has added five new, differentiated products to its portfolio to meet the needs of SeraCare’s growing customer base in the life sciences industry.

9 Jan 2010

Researchers discover rules that dictate the three-dimensional shapes of RNA molecules

University of Michigan researchers have discovered the rules that dictate the three-dimensional shapes of RNA molecules, rules that are based not on complex chemical interactions but simply on geometry.

8 Jan 2010

NEB introduces Lemo21(DE3) Competent E. coli

New England Biolabs (NEB) has introduced Lemo21(DE3) Competent E. coli, a tunable T7 expression strain optimized for the expression of difficult constructs, including membrane proteins, toxic proteins and proteins prone to insoluble expression.

From New England Biolabs 8 Jan 2010

Mutations in genome regulation machinery identified in clear cell renal cell carcinoma

In a new study, scientists have searched for mutations in the gene regions of more than 100 kidney cancer samples, the largest number of samples from a single tumour type to be sequenced to date.

7 Jan 2010

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has received a milestone payment from its partner Roche related to initiation of pre-IND (investigational new drug application) studies for an RNAi therapeutics product candidate.

7 Jan 2010

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Gilead Sciences, Inc. today announced that a Phase II clinical trial of its investigational integrase inhibitor-based, once-daily, fixed-dose “Quad” regimen of elvitegravir, GS 9350 and Truvada® (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV-1 infection met its primary objective.

7 Jan 2010

Agilent Technologies, Covaris sign co-marketing agreement to streamline next-generation sequencing experiments

Agilent Technologies, Inc. (NYSE:A) and Covaris Inc. today announced a co-marketing agreement in which Covaris S2 DNA shearing technology will be marketed with the Agilent SureSelect Target Enrichment System to streamline next-generation sequencing experiments.

6 Jan 2010

Scientists determine how RNAi, a biological response to RNA, can regulate gene expression

A team of scientists at Cold Spring Harbor Laboratory (CSHL) has determined a hierarchical set of criteria that explain how the molecular precursors of gene-regulating small RNAs are sorted by the cellular machinery.

5 Jan 2010

Peginterferon alpha-2a yields better results in treating patients with chronic hepatitis C

In patients with chronic hepatitis C, treatment with peginterferon alpha-2a (PegIFNα2a) plus ribavirin (RBV) better suppresses the virus to undetectable levels in the blood than treatment with peginterferon alpha-2b (PegIFNα2b) plus RBV, according to two new head-to-head studies in Gastroenterology, the official journal of the American Gastroenterological Association (AGA) Institute.

5 Jan 2010

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

Dicerna Pharmaceuticals, Inc., (Dicerna) a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology™ and Dicer Substrate siRNA (DsiRNA) molecules, and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin), one of Japan's leading biopharmaceutical companies, announced today that the two companies have entered into a research collaboration and license agreement for the research, development and commercialization of drug delivery systems and DsiRNA pharmaceuticals for therapeutic targets in oncology.

4 Jan 2010

Research may point to more effective therapeutic targets for prion diseases

Scientists from The Scripps Research Institute have determined for the first time that prions, bits of infectious protein devoid of DNA or RNA that can cause fatal neurodegenerative disease, are capable of Darwinian evolution.

4 Jan 2010

Scientists discover a new family of giant virus

After Mimivirus, Mamavirus and the virophage, the group of giant viruses now has a new member called Marseillevirus. Discovered in an amoeba by the team led by Didier Raoult at the Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes research group (CNRS/Université Aix-Marseille 2), a description of this new virus was published this week on the website of the Proceedings of the National Academy of Sciences (PNAS).

31 Dec 2009

Study suggests genetic variations predispose African-Americans to diabetes

For years, scientists have tried to determine the basis for discrepancies between race and the predisposition for development of diseases such as type II diabetes and cardiovascular disease. Could factors such as differences in lifestyle or access to health care play a role, or is there something else in play?

29 Dec 2009

Successful RNA interference to turn off multiple genes raises hope for new liver disease treatments

Researchers at MIT and Alnylam Pharmaceuticals report this week that they have successfully used RNA interference to turn off multiple genes in the livers of mice, an advance that could lead to new treatments for diseases of the liver and other organs.

29 Dec 2009

Scientists uncover a central process in memory encoding

Scientists at UC Santa Barbara have made a major discovery in how the brain encodes memories. The finding, published in the December 24 issue of the journal Neuron, could eventually lead to the development of new drugs to aid memory.

24 Dec 2009

Nationwide Children's Hospital chosen as a BCR for TCGA

Nationwide Children's Hospital recently was awarded an initial $5.5 million contract from the National Cancer Institute (NCI) to serve as a Biospecimen Core Resource (BCR) for The Cancer Genome Atlas (TCGA), a program co-managed by the NCI and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health (NIH).

23 Dec 2009

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

No two tumors are alike, but analyzing the genetics of cancers from different parts of the body may reveal surprising details useful for treatment and prevention.

22 Dec 2009

Tel Aviv University's new Genome Analyzer fuels research dreams and tomorrow's cures

To identify the hemophilia mutation that affected Queen Victoria and her European relatives, scientific detectives used a cutting-edge "deep sequencing tool." Able to trace rare genetic disease mutations, the tool can turn a single laboratory into a fertile genetic research center.

22 Dec 2009

Findings may help develop new antiviral drugs for influenza

Investigators at Burnham Institute for Medical Research (Burnham), Mount Sinai School of Medicine (Mount Sinai), the Salk Institute for Biological Studies (Salk) and the Genomics Institute of the Novartis Research Foundation (GNF) have identified 295 human cell factors that influenza A strains must harness to infect a cell, including the currently circulating swine-origin H1N1.

22 Dec 2009

RNA News and Research

Further Reading

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

SeraCare Life Sciences launches new products to aid discovery and development of drugs and diagnostics

Researchers discover rules that dictate the three-dimensional shapes of RNA molecules

NEB introduces Lemo21(DE3) Competent E. coli

Mutations in genome regulation machinery identified in clear cell renal cell carcinoma

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

Phase II clinical trial of Gilead Sciences' elvitegravir, GS 9350 and Truvada meets primary objective

Agilent Technologies, Covaris sign co-marketing agreement to streamline next-generation sequencing experiments

Scientists determine how RNAi, a biological response to RNA, can regulate gene expression

Peginterferon alpha-2a yields better results in treating patients with chronic hepatitis C

Dicerna Pharmaceuticals and Kyowa Hakko Kirin sign research collaboration and license agreement

Research may point to more effective therapeutic targets for prion diseases

Scientists discover a new family of giant virus

Study suggests genetic variations predispose African-Americans to diabetes

Successful RNA interference to turn off multiple genes raises hope for new liver disease treatments

Scientists uncover a central process in memory encoding

Nationwide Children's Hospital chosen as a BCR for TCGA

New project analyzes genetic sequence and variations of every gene expressed by 1,000 tumors

Tel Aviv University's new Genome Analyzer fuels research dreams and tomorrow's cures

Findings may help develop new antiviral drugs for influenza

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo